Denali Therapeutics GAAP EPS of -$0.72 in-line

2 hours ago 1
  • Denali Therapeutics press release (NASDAQ:DNLI): Q2 GAAP EPS of -$0.72 in-line.
  • Cash, cash equivalents, and marketable securities were approximately $977.4 million as of June 30, 2025.

Recommended For You

More Trending News

About DNLI Stock

Related Stocks

Read Entire Article